<table>
<thead>
<tr>
<th>Title</th>
<th>1st Author</th>
<th>Author List</th>
<th>SCRI Affiliated Physician Coauthors</th>
<th>ASCO Selection Status</th>
<th>Session Title</th>
<th>Date</th>
<th>Time Begin</th>
<th>Time End</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preliminary Findings from a Phase I, Multi-center, Open-label Study of the anti-CD20 Antibody Drug Conjugate (ADC), IMGN529, in Adult Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma</td>
<td>A Stathis</td>
<td>A Stathis, K Maddeocks, A Ilen, A Maga, MJ Palomba, S Zidjlin, M Murphy, JD Decker, RJ Rico-Seta, A Freedman</td>
<td>F Film</td>
<td>Poster Highlights</td>
<td>Lymphoma and Plasma Cell Disorders</td>
<td>5/30/2014</td>
<td>1:00pm</td>
<td>4:00pm</td>
<td>5045</td>
</tr>
<tr>
<td>Activity of TGR-024, a Novel Once Daily PI3Kδ inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies</td>
<td>MA Burris</td>
<td>MA Burris, M Patel, MC Lamas, D Branden, DA O'Connor, C Deng, M Gutierrez, SF Jones, JK Gue, MP Minik, P Sportelli, S Vakkalanka, HJ Film</td>
<td>MA Burris, SF Jones, JW Film</td>
<td>Poster Highlights</td>
<td>Developmental Therapeutics - Clinical Pharmacology &amp; Experimental Therapeutics</td>
<td>5/30/2014</td>
<td>1:00pm</td>
<td>4:00pm</td>
<td>5045</td>
</tr>
<tr>
<td>Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or refractory, refractory multiple myeloma</td>
<td>TM Bauer</td>
<td>TM Bauer, D Spigel, Z Ma, HT Arkenau, P Chandra, JL Precott, CM Lane, SF Jones, DW Taxilcy, JC Bendell, MA Burris, JR Infante</td>
<td>HT Arkenau, CR Lemech</td>
<td>Poster Highlights</td>
<td>Lymphoma and Plasma Cell Disorders</td>
<td>5/30/2014</td>
<td>1:00pm</td>
<td>4:00pm</td>
<td>5045</td>
</tr>
<tr>
<td>Preclinical data from a phase I study of the single-agent CDK4/6 inhibitor LEE011 in patients (pts) with advanced solid tumors</td>
<td>J Bendell</td>
<td>J Bendell, G Shapiro, EA Sauvage, SF Jones, JF Hilton, D Shkolny, R Bluck, DA Bergstrom</td>
<td>J Bendell, SF Jones</td>
<td>Poster Highlights</td>
<td>Developmental Therapeutics - Clinical Pharmacology &amp; Experimental Therapeutics</td>
<td>5/30/2014</td>
<td>1:00pm</td>
<td>4:00pm</td>
<td>5045</td>
</tr>
<tr>
<td>Acosta S, 5th-1st human trial on KMT-132, a polymer-conjugated fumagillo derivative, in patients (pts) with advanced solid tumors and lymphomas</td>
<td>J Infante</td>
<td>J Infante, G Shapiro, P Witteveen, JF Gerecitano, V Bilbag, J Choup, I Isaac, A Chakraborty, A Matina, X Zhao, S Passuwan, P Ezzier</td>
<td>J Infante</td>
<td>Poster Highlights</td>
<td>Developmental Therapeutics - Clinical Pharmacology &amp; Experimental Therapeutics</td>
<td>5/30/2014</td>
<td>1:00pm</td>
<td>4:00pm</td>
<td>5045</td>
</tr>
<tr>
<td>Efficacy of idelalisib in CLL subpopulations harboring del(11q) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial</td>
<td>TJ Tang</td>
<td>TJ Tang, WC So, GM Nian, WF Lu, TM Bauer, J Infante, RT-P Poon, DS Hong, CC Lin, PB Young, Z Zhao, A Kumar, M Aliniou, B Ma</td>
<td>TJ Tang</td>
<td>Poster Highlights</td>
<td>Lymphoma, Myelodysplasia, and Transplantation</td>
<td>5/30/2014</td>
<td>11:30am</td>
<td>2:30pm</td>
<td>4055</td>
</tr>
<tr>
<td>Phase II Study of Daunorubicin in Patients with Documented Malignant Gastric/Esophageal Tumors</td>
<td>KC Shih</td>
<td>KC Shih, P Patel, N Butwala, J Bach, D Brown, WI Garner, A Sarr, R Schwartz, S Kamei, L Lopez, HA Burris, III</td>
<td>KC Shih, HA Burris, III</td>
<td>General Poster Session</td>
<td>Central Nervous System Tumors</td>
<td>5/31/2014</td>
<td>8:00am</td>
<td>11:45am</td>
<td>5 Hall A2</td>
</tr>
<tr>
<td>Impact of PI3Kβ inhibition on efficacy of Panitumumab (X-PECT): A Phase II randomized study of P + capcitabine (PC) vs. placebo + capcitabine (PC) in refractory metastatic colorectal cancer (mCRC) patients</td>
<td>JC Eng</td>
<td>JC Eng, J Bendell, S Koptes, E Tsuts, KO Xia, JY Wang, X Wang, J Phillips, P Sportelli, M Berson</td>
<td>JC Eng</td>
<td>General Poster Session</td>
<td>Gastrointestinal (Colorectal) Cancer</td>
<td>5/30/2014</td>
<td>8:00am</td>
<td>11:45am</td>
<td>5 Hall A2</td>
</tr>
<tr>
<td>Phase I Study of the selective BRAF/MEK inhibitor, vemurafenib (GSK1120212), combined with cetuximab and with or without the specific PI3K inhibitor BAY 87-2683 in patients with BRAF mutant colorectal cancer</td>
<td>RV Geel</td>
<td>RV Geel, JF Elia, JC Bendell, JF Poon, JH Kab مهمانی, KE Colhoun, I Phillips, E Sparrow, P Kavan, J-P Delord, MH Schreiber, ZA Wierzbowski, Y Yamasaki, T Yoshino, T Demuth E Schellens</td>
<td>JC Bendell</td>
<td>General Poster Session</td>
<td>Gastrointestinal (Colorectal) Cancer</td>
<td>5/31/2014</td>
<td>8:00am</td>
<td>11:45am</td>
<td>5 Hall A2</td>
</tr>
<tr>
<td>Efficiency and Tolerability in an Open-Label Phase II Study of MEK Inhibitor Trametriscine (T), BRAF Inhibitor Dabrafenib (D) and Anti-EGFR Antibody Panitumumab (P) in Combination in Patients (pts) with BRAF V600E Mutated Colorectal Cancer</td>
<td>J Bendell</td>
<td>J Bendell, CE Ayres, A Andes, J Tabares, A Gordon, R Bernardo, E Van Cutsem, S Tager, R Solis, WT Ca, A Alifret, M Mottini, P Mottini, P Pali, Y Wail, A Hoss, K Otter, W Conover, JHM Schellens</td>
<td>J Bendell</td>
<td>General Poster Session</td>
<td>Gastrointestinal (Colorectal) Cancer</td>
<td>5/31/2014</td>
<td>8:00am</td>
<td>11:45am</td>
<td>5 Hall A2</td>
</tr>
<tr>
<td>STEAP: a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOX-BEVT (bevacizumab (BEV) vs FOLFOX-BEVT for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC)</td>
<td>J Bendell</td>
<td>J Bendell, B Tan, J Reeves, H Xiong, R Laronde, P Bytik, N Connor, M Hurnecke</td>
<td>J Bendell</td>
<td>General Poster Session</td>
<td>Gastrointestinal (Colorectal) Cancer</td>
<td>5/31/2014</td>
<td>8:00am</td>
<td>11:45am</td>
<td>5 Hall A2</td>
</tr>
</tbody>
</table>
Exploratory biomarker analysis of a phase I study of MK-2994, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors

E Kilgour, D Ferry, M Saggese, HT Arkenau, C Rooney, NR Smith
Oral Abstract Session
Clinical Science Symposium: Advances in Tumor Biology
11:30am (Actual: 11:24am)
9:30am (Actual: 9:30am)
All Hallows Theatre

Relationship of pharmacokinetics (PK), toxicity and initial evidence of clinical activity in patients (pts) with metastatic uveal melanoma (MUM) with drug exposure and toxicity for sorafenib

Oral Abstract Session
Clinical Science Symposium: Melanoma/Skin Cancer
8:00am (Actual: 8:05am)
9:30am (Actual: 9:25am)
E Arie Crown Theatre

Phase 1 study of oral 4-1BB/CTLA-4 agonist immunoglobulin (4IgG4)2/CTLA-4, a novel PD-1 ligand blocker: preliminary results from a phase 1 dose escalation study in patients (pts) with advanced solid tumors

R Klok, B Ahn, S Kim, C Staal, J-Z Lin, WJ Hough, J-C Yang, C Collin, M Saggese, HT Arkenau
General Poster Session
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
12:30pm (Actual: 12:32pm)
1:00pm (Actual: 12:59pm)
E Hall D1

Multi-arm, nonrandomized, open-label phase IIb study to evaluate PHX-010/PG-SGA and chemotherapy in patients with small cell lung cancer

R Gonzalez, S Rizk, E Husain, A Sultana, J Sultana, P Cao, L Ma, J Brown, E Kilgour
General Poster Session
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
1:45pm (Actual: 1:47pm)
2:15pm (Actual: 2:13pm)
E Hall D2

Feasibility of circulating tumour cell (CTC) enumeration and molecular profiling (MP) as a biomarker in advanced endometrial cancer (EC)

CM Lemerch, J Ehrlich, A Paterson, E Kenworthy, M Lewis, N Griffin, E Arna, HT Arkenau, M Chiasson, M Eichhorn, K Hjelm, L Jandl
Oral Abstract Session
General Poster Session
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
8:00am (Actual: 7:54am)
9:30am (Actual: 9:25am)
All Hallows Theatre

Intratumoral metabolic changes measured with 18F-FDG PET/CT parametric response maps correlate with concentrations of CC-122, a TGF-α1/2 biomarker inhibitor in human glioblastoma

BM Elsinger, TP Klemp, P Munder, KE Shih, M Saggese, J Bendell, A James, T Ng, E Granger, A Hege
General Poster Session
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
8:00am (Actual: 7:54am)
9:30am (Actual: 9:25am)
All Hallows Theatre

A phase 1 trial and pharmacokinetic study of nxv-001, a novel ROS-mediated pan-epigenetic agent

T Reid, B Oronsky, JR Infante, HA Harris, C Schilcher, SJ Knox, JZ Stephens, G Fang, J Szczesniak
Oral Abstract Session
Clinical Science Symposium: Melanoma/Skin Cancer
8:00am (Actual: 8:05am)
9:30am (Actual: 9:25am)
All Hallows Theatre

A phase-1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor, AZD4779, in patients (pts) with advanced gastric (GC) and gastroesophageal junction (GEJ) cancer

HT Arkenau, M Saggese, A Hollebecque, A Mathewson, C Rooney, D Lender, P Freier, E Kilgour, N Brooks
General Poster Session
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
8:00am (Actual: 7:54am)
9:30am (Actual: 9:25am)
All Hallows Theatre

Phase II trial of oral irinotecan in the treatment of metastatic colorectal cancer

M Callahan, JC Bendell, E Chen, M Morse, N Amin, P Bono, B Jonker, TRJ Evans, O Villani, O Christensen, A Amin
Oral Abstract Session
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
8:00am (Actual: 7:54am)
9:30am (Actual: 9:25am)
All Hallows Theatre

A Phase III study of oral brentuximab vedotin (T-DM1) in patients (pts) with de novo, relapsed or refractory CD30+ hematologic or solid tumors

E Ayala, D Fong, C Franklin, S Bhansali, K Wan, B Hewes, D Junic
Oral Abstract Session
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
8:00am (Actual: 7:54am)
9:30am (Actual: 9:25am)
All Hallows Theatre
Final results of a phase II study of ramucirumab (RAM) plus cisplatin (C) versus C in advanced metastatic breast cancer (MBC)

DA Yardley, PD Richards, JR Rees, EC Deer, C Osborne, M Salwen, D Paul, PA Ardern-Jones, TM Guthrie, JL Bourmond, Y Xu, AR Ibrahim

DA Yardley

General Poster Session
Breast Cancer - Triple-Negative/Cytotoxic/Local Therapy
6/2/2014 8:00am 11:45am S Hall A2

A phase II study with lead-in safety cohort of capecitabine (C) plus lapatinib (L) as therapy for HER2+ metastatic breast cancer (MBC) with intracranial metastases (mets)

DA Yardley

General Poster Session
Breast Cancer - HER2/ER
6/2/2014 8:00am 11:45am S Hall A2

A randomized double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of sunitinib in combination with everolimus in patients with previously untreated advanced renal cell carcinoma (mRCC)

HL Hammers

General Poster Session
Genitourinary (Nonprostate) Cancer
6/2/2014 8:00am 11:45am S Hall A2

A Multi-Center, Open-Label, Single-Arm, Phase 2 Study of the SUPI Inhibitor Sonepcizumab (LT1009) in Patients with Previously Treated Metastatic Renal Cell Carcinoma (mRCC)

HC Hammers, JR Infante, JM Halverson, K Kurioka, P Menchala, A Pinzino, D Groshong, JD Hainsworth, JD Hainsworth, JR Infante

General Poster Session
Genitourinary (Nonprostate) Cancer
6/2/2014 1:15pm 5:00pm S Hall A2

A phase II/III study to assess the safety and efficacy of pazopanib and MK-4455 in subjects with advanced renal cell carcinoma

SF McDermott

General Poster Session
Genitourinary (Nonprostate) Cancer
6/2/2014 8:00am 11:45am S Hall A2

A phase I/II study to assess safety, pharmacokinetics, and effects on circulating cytokines in women with advanced hormone-positive breast cancer

LS Schwartzberg

General Poster Session
Breast Cancer - HER2/ER
6/2/2014 8:00am 11:45am S Hall A2

A single arm, open-label, phase 2 study of MCA022 (FC-optimal Chimeric Anti-HER2 Monoclonal Antibody (mAb)) in patients with Relapsed or Refractory Advanced Breast Cancer Whose Tumors Express HER2 at the 2+ level by Immunohistochemistry and Lack Evidence of HER2 Gene Amplification by FISH

MD Pegram

General Poster Session
Breast Cancer - HER2/ER
6/2/2014 8:00am 11:45am S Hall A2

A phase 2 randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of azaclidine in combination with everolimus in estrogen or progesterone receptor-positive and HER2 normal advanced breast cancer

DA Yardley

General Poster Session
Breast Cancer - HER2/ER
6/2/2014 8:00am 11:45am S Hall A2

Enzalutamide plus exemestane: a pilot study to assess safety, pharmacokinetics, and effects on circulating estrogens in women with advanced hormone-positive breast cancer

LS Schwartzberg, DA Yardley, AD Elias, MR Patel, A Gucalp, HA Burris

General Poster Session
Breast Cancer - HER2/ER
6/2/2014 8:00am 11:45am S Hall A2

A phase I/II study to assess safety, pharmacokinetics, and effects on circulating cytokines in subjects with advanced renal cell carcinoma

SF McDermott

General Poster Session
Genitourinary (Nonprostate) Cancer
6/2/2014 8:00am 11:45am S Hall A2
Long-term follow-up of a phase 1 study of ponatinib in patients with Philadelphia chromosome-positive leukemia

M Talpaz, JE Cortes, H Kantarjian, NP Shah, D Bixby, J Finn, T D’Hanns, S Hu, T Cleveland, VM Rivera, CD Turner, FG Haluska, JW Druker, ML Mauro, IW Flinn

General Poster
Session Leukemia, Myelodysplasia, and Transplantation 6/3/2014 9:45am (Actual: 11:45am) 2:15pm 3:45pm S Hall A3

A randomized double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR-positive (IHC/FISH) non-small cell lung cancer (NSCLC): Radiant results

K Kelly

General Poster
Session Lung Cancer - Non-Small Cell Regional/Small Cell/Other Thoracic Cancers 6/4/2014 9:45am (Actual: 11:45am) 2:15pm 3:45pm S Hall A3

DYNAMO™: A Phase 2 Trial of the PI3K-δ, γ-inhibitor IPI-145 in Patients with Refractory Indolent Non-Hodgkin Lymphoma

N Wagner-Johnston

General Poster
Session Lymphoma and Plasma Cell Disorders 6/2/2014 1:15pm 5:00pm S Hall A2

Onartuzumab + erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled metling (OAM4971g) global trial

K Lewis

Poster Highlights
Session Lung Cancer - Non-small Cell Metastatic 6/2/2014 8:00am 11:00am E354b

A phase I trial of x-396, a novel ALK inhibitor, in patients with advanced solid tumors.

L Horn

Poster Highlights
Session Lung Cancer - Non-small cell Metastatic 6/3/2014 8:00am 11:00am E 354b

Determination of the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases:

K Lewis

Poster Highlights
Session Melanoma - Skin Cancer 6/2/2014 8:00am 11:00am E354a

Phase II study of FOLFIRI plus panitumumab (pani) followed by evaluation for resection, in patients (pts) with metastatic KRAS wild-type colorectal cancer (mCRC) with liver metastases only

A Zakari

Publication only (e14552)

Food Effect Sub Study of a Phase 3 Randomized Double-blind Trial of Maintenance with Niraparib (MK4827), a Poly(ADP)ribose Polymerase (PARP) Inhibitor versus Placebo in Patients with Platinum Sensitive Ovarian Cancer

K Moore

Publication only (e18510)

Phase II trial of preoperative carboplatin (carbo)/pemetrexed (pem) in patients (pts) with select stage IB-IIIA non-squamous non-small-cell lung cancer (NS-NSCLC)

K Moore

Publication Only

Patient-Reported Outcomes Data from A Phase 2 Study of idelalisib in Patients with Refractory Indolent B-cell Non-Hodgkin Lymphoma (iNHL)

4. Mas, TM Bauer, D Haynes, J Prescott, DM Stults, SF Jones, JD Hainsworth, JR Infante, HA Burris III, DR Spigel

Publication Only
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Publication Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase I/II study of TSR-011, A Potent Inhibitor of ALK and TRK, including Crizotinib-Resistant Mutations</td>
<td>GJ Weiss, JC Sachdev, JR Infante, HM Hata, N Natoli, HT Arkenau, KM Wicson, Y Karou, K Lukin, L Hughes, RE Martell, SP Anthony</td>
<td>Publication only</td>
</tr>
<tr>
<td>Comorbidity, metastases, and survival in women with metastatic breast cancer (mBC) receiving HER2-targeted agents (H2Ts)</td>
<td>NM Meyer, Y Has, X Song, W Johnson, N Shi, J Rogerio, DA Yardley</td>
<td>Publication only</td>
</tr>
<tr>
<td>Disease and treatment (tx) characteristics in women with metastatic breast cancer (mBC) receiving HER2-targeted agents (H2Ts)</td>
<td>W Johnson, NM Meyer, Y Has, X Song, N Shi, J Rogerio, DA Yardley</td>
<td>Publication only</td>
</tr>
<tr>
<td>Healthcare utilization and costs in women with metastatic breast cancer (mBC) receiving HER2-targeted agents (H2Ts)</td>
<td>X Song, Y Has, NM Meyer, W Johnson, N Shi, J Rogerio, DA Yardley</td>
<td>Publication only</td>
</tr>
<tr>
<td>A tool to help research programs exceed the minimum standards of conducting clinical research.</td>
<td>PS Graham, RY Smith, PA Hurley</td>
<td>Publication only</td>
</tr>
</tbody>
</table>